4/8
08:20 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
4/8
08:06 am
prax
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies [Yahoo! Finance]
High
Report
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies [Yahoo! Finance]
4/8
08:00 am
prax
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
High
Report
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
4/3
05:00 pm
prax
Praxis Precision Medicines to Participate in Upcoming April Conferences
Medium
Report
Praxis Precision Medicines to Participate in Upcoming April Conferences
4/3
04:00 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31
07:11 am
prax
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
3/24
08:08 am
prax
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]
3/24
08:00 am
prax
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
Low
Report
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
3/4
05:00 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4
08:00 am
prax
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
High
Report
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
3/4
05:36 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) was downgraded by analysts at Wedbush from a "hold" rating to a "strong sell" rating.
High
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) was downgraded by analysts at Wedbush from a "hold" rating to a "strong sell" rating.
3/3
11:30 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Truist Financial Co. from $175.00 to $85.00. They now have a "buy" rating on the stock.
High
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Truist Financial Co. from $175.00 to $85.00. They now have a "buy" rating on the stock.
3/3
08:10 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Needham & Company LLC from $150.00 to $85.00. They now have a "buy" rating on the stock.
High
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Needham & Company LLC from $150.00 to $85.00. They now have a "buy" rating on the stock.
3/3
08:10 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at HC Wainwright from $120.00 to $105.00. They now have a "buy" rating on the stock.
High
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at HC Wainwright from $120.00 to $105.00. They now have a "buy" rating on the stock.
3/3
08:10 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Robert W. Baird from $117.00 to $73.00. They now have an "outperform" rating on the stock.
High
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target lowered by analysts at Robert W. Baird from $117.00 to $73.00. They now have an "outperform" rating on the stock.
3/1
06:50 am
prax
Health Care Roundup: Market Talk [Yahoo! Finance]
High
Report
Health Care Roundup: Market Talk [Yahoo! Finance]
2/28
07:07 pm
prax
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
2/28
08:00 am
prax
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
High
Report
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
2/11
07:27 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $111.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $111.00 price target on the stock.
2/10
08:00 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
2/4
05:00 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/3
05:00 pm
prax
Praxis Precision Medicines to Present at Two February Investor Conferences
Medium
Report
Praxis Precision Medicines to Present at Two February Investor Conferences
1/21
12:19 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Truist Financial Co. from $150.00 to $175.00. They now have a "buy" rating on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Truist Financial Co. from $150.00 to $175.00. They now have a "buy" rating on the stock.